A test that uses artificial intelligence (AI) to analyze genetic data from a vaginal swab can detect endometrial cancer with high diagnostic accuracy, a new…
Gynecological cancer
GYNECOLOGICAL CANCER
FDA fast tracks treatment for advanced, resistant ovarian cancer
The U.S. Food and Drug Administration (FDA) has granted fast-track designation to the experimental therapy ZW191 as a potential treatment for hard-to-manage ovarian cancer.
GYNECOLOGICAL CANCER
Overt forms advisory board to guide ovarian cancer therapy push
Overt Bio said it established a clinical advisory board to support the development of OVT-101, its lead investigational CAR T-cell therapy for ovarian cancer,…
GYNECOLOGICAL CANCER
New CAR-NKT cell therapy targets endometrial cancer on two fronts
Researchers have developed a new cell therapy that aims to treat endometrial cancer by targeting cancer cells while also depleting immune cells that help protect…
GYNECOLOGICAL CANCER
Immune duo safely targets hard-to-treat gynecological cancers
A combination of two immune-modulating treatments, Lymphir (denileukin diftitox) and Keytruda (pembrolizumab), was well tolerated in an exploratory clinical trial of people with hard-to-treat…
GYNECOLOGICAL CANCER
New trial data show alnodesertib may slow ovarian cancer progression
A low dose of alnodesertib added to standard chemotherapy significantly reduced the likelihood of disease progression among people with platinum-resistant high-grade serous ovarian carcinoma (HGSOC)…
GYNECOLOGICAL CANCER
FDA approves Keytruda for hard-to-treat gynecological cancers
People in the U.S. with certain gynecological cancers that are resistant to first-line chemotherapies now have a new treatment option: The U.S. Food and Drug…
GYNECOLOGICAL CANCER
Elenagen helps women with ovarian cancer live 1 year longer
Adding Elenagen, Curelab Oncology’s experimental anticancer medication, to gemcitabine chemotherapy may help women with treatment-resistant ovarian cancer live significantly longer. Those are the results…
GYNECOLOGICAL CANCER
Ovarian cancer drug lira-cel extends survival ‘far longer’ than expected
In an early clinical trial in the U.S., most women with hard-to-treat ovarian cancer given a low dose of cell therapy candidate liraltagene autoleucel,…
GYNECOLOGICAL CANCER
Prostate cancer tool may cut risk for women in radiation therapy
A long-lasting gel used to help protect the bowel during radiation therapy for prostate cancer may be successfully used in women with gynecological cancers…
Recent Posts
- I’m taking up walking to combat the fog of ‘chemo brain’
- FDA OKs first-in-human trial of cell therapy for hard-to-treat AML
- First-of-its-kind solid tumor cell therapy prepares to debut in China
- Patients and caregivers can tap into the power of humor, too
- New brain cancer treatment for children awarded FDA orphan status
